The severe cardiorenal syndrome: 'Guyton revisited'. - Test2 - elhamkhani - TriplyDB

The severe cardiorenal syndrome: 'Guyton revisited'.

The severe cardiorenal syndrome: 'Guyton revisited'.

http://www.wikidata.org/entity/Q34379161

about

Renal dopaminergic system: Pathophysiological implications and clinical perspectives Loss-of-function DNA sequence variant in the CLCNKA chloride channel implicates the cardio-renal axis in interindividual heart failure risk variation Renocardiac syndromes: physiopathology and treatment stratagems The renal nerves in chronic heart failure: efferent and afferent mechanisms Target organ cross talk in cardiorenal syndrome: animal models Urinary Proteolytic Activation of Renal Epithelial Na+ Channels in Chronic Heart Failure.Cardiorenal Syndrome Type 1 May Be Immunologically Mediated: A Pilot Evaluation of Monocyte Apoptosis.Clinical features of patients with stress-induced cardiomyopathy associated with renal dysfunction: 7 case series in single center.Cardiac and renal function are progressively impaired with aging in Zucker diabetic fatty type II diabetic rats Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative Increased Serum Uric Acid Level Is a Risk Factor for Left Ventricular Hypertrophy but Not Independent of eGFR in Patients with Type 2 Diabetic Kidney Disease Epidemiology of chronic kidney disease in heart failure.Left atrial volume and adverse cardiovascular outcomes in unselected patients with and without CKD.Virtual patients and sensitivity analysis of the Guyton model of blood pressure regulation: towards individualized models of whole-body physiology Short-term erythropoietin treatment does not substantially modulate monocyte transcriptomes of patients with combined heart and renal failure Atherosclerotic renal artery stenosis is prevalent in cardiorenal patients but not associated with left ventricular function and myocardial fibrosis as assessed by cardiac magnetic resonance imaging.Therapeutic options for the management of the cardiorenal syndrome.The cardiorenal syndrome: a review Cardiorenal syndrome caused by heart failure with preserved ejection fraction Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial.Volumetric Response beyond Six Months of Cardiac Resynchronization Therapy and Clinical Outcome.Clinical features of cardio-renal syndrome in a cohort of consecutive patients admitted to an internal medicine ward.Left ventricular assist devices: a kidney's perspective.The kidney in heart failure: an update.The cardio-renal-anaemia syndrome predicts survival in peritoneally dialyzed patients Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation.Characterization of a murine model of cardiorenal syndrome type 1 by high-resolution Doppler sonography.Shen-Kang protects 5/6 nephrectomized rats against renal injury by reducing oxidative stress through the MAPK signaling pathways.Outcome of hepatectomy for hepatocellular carcinoma in patients with renal dysfunction Effects of statins on cardiorenal syndrome.Circulatory syndrome: an evolution of the metabolic syndrome concept!Gastrectomy for patients with gastric cancer and non-uremic renal failure.Troponin T as a Predictor of End-Stage Renal Disease and All-Cause Death in African Americans and Whites From Hypertensive Families Associations between kidney function and subclinical cardiac abnormalities in CKD.Systems biology and biomechanical model of heart failure Impact of Impaired Renal Function on the Incidence of Atrial Fibrillation following Radiofrequency Ablation of Cavotricuspid Isthmus-Dependent Atrial Flutter.Long-term changes in renal function and perfusion in heart failure patients with reduced ejection fraction.Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors.Pathophysiological model of chronic heart failure complicated with renal failure caused by three-quarter nephrectomy and subcutaneous injection of isoprenaline.Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers.

P2860

Q22241156-DBD9F597-29D4-4E81-87ED-95A5C098EFD8 Q24625036-03393716-7D2B-46AC-A029-A4C57B6A00BE Q26781936-F60A9145-D47B-4F61-9383-9CD52DBAB90B Q26795502-D54C8B80-FBA6-49E6-8184-CAEEAF9B21A7 Q26851343-E9D5BF89-601E-41D7-871C-DFEB630B9A32 Q30315923-9830BA08-DABA-450C-AD4C-4EC7F09D1DCD Q30427437-6DCFB270-EFE4-45C9-979D-F5958F4F1773 Q31141078-A1ACB2DB-4174-4F62-9B38-FBD2B3665059 Q33717027-50C92646-944C-416D-8C8D-430802D6A0CF Q33728260-46ADE52E-E792-41BC-AE32-EFD7D2C3D0B6 Q33868118-4E44862A-65E1-46E5-957D-EAD8BC302933 Q33978466-8F849090-4951-4379-A642-4D8A5801B891 Q34008906-0B20C38C-FF5F-4219-A6F5-76549C056C08 Q34325461-E89E6946-6725-4727-89C8-E1F755DF6788 Q34407902-2A67632A-DF9F-4074-8B95-ADC7BF59A114 Q34417974-F12CB159-951F-4946-B193-753D729906FB Q34442587-5B225D6F-5C0C-48B3-A6E6-70DD794074C8 Q34495307-CC9BA230-C2B0-4196-9278-105796BB5ADC Q34571610-19FB49E7-2F6C-4EF5-9186-90306FD87D3B Q35079951-760C76E4-EC81-470E-91C6-01DBE378E80B Q35560785-E78F0C8C-A68E-4312-8DF2-8A30FCCE2983 Q35622822-F37D2446-C06A-4069-8E39-0BCBA9CE6C45 Q35726089-24FC67E5-85ED-40EF-9603-090577FBFF87 Q35737499-EDDC1D1B-75A2-4E66-93A2-46BE7BB83E35 Q35770743-C344E758-3F23-4E9F-8C48-2A5495A64910 Q35842921-22677FFD-3BA7-42D9-9BBA-128BB582AB81 Q35929205-A590793A-FC16-4B15-8965-4E3845F5C8BB Q36041743-0EBF11AE-7B5F-40B9-AD98-486B09E87E41 Q36063271-3EBB02AD-6950-4D62-AC25-826007DA95C7 Q36077149-FBDB7AC0-7650-4942-97B3-97BDE149EFB4 Q36087928-E1214BF7-EDF9-4DFB-B4F4-17D559AA82AF Q36179933-881E574D-F416-43E5-94DE-CC4EDEE73C22 Q36259639-AF7CC88F-D205-4560-B806-5358A34948F2 Q36280359-48E18BC0-D85F-4EA7-BB4F-BEE4112AFB63 Q36302132-2AD7DF8A-C212-4962-A273-22C08755E972 Q36323356-2C39A92A-A2A3-41FA-AE8D-C518D4218CA6 Q36460470-B41C29E2-966B-480A-95CA-BD8B2AAF3082 Q36555238-21118F36-2219-46CC-9739-D1C4CA7EC9E3 Q36603487-130DACF0-0EB1-40C7-8F00-2296064120C4 Q36716456-A23EE014-47FE-40E1-9C7C-1475CAADBB80

P2860

The severe cardiorenal syndrome: 'Guyton revisited'.

http://www.wikidata.org/entity/Q34379161

description

2004 nî lūn-bûn

@nan

2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

The severe cardiorenal syndrome: 'Guyton revisited'.

@ast

The severe cardiorenal syndrome: 'Guyton revisited'.

@en

The severe cardiorenal syndrome: 'Guyton revisited'.

@nl

type

label

The severe cardiorenal syndrome: 'Guyton revisited'.

@ast

The severe cardiorenal syndrome: 'Guyton revisited'.

@en

The severe cardiorenal syndrome: 'Guyton revisited'.

@nl

prefLabel

The severe cardiorenal syndrome: 'Guyton revisited'.

@ast

The severe cardiorenal syndrome: 'Guyton revisited'.

@en

The severe cardiorenal syndrome: 'Guyton revisited'.

@nl

P1433

Q34379161-E8B7E637-8108-49BE-B928-4DF6553B4914

P1476

Q34379161-EADC9E00-4004-45E7-9E0B-06AF27D7648B

P2093

Q34379161-1F92CBCE-5665-45BA-BCA1-A382C33EB714

Q34379161-3AA7B314-F958-421E-8142-CC0BA02FB73C

Q34379161-765C1207-DCD5-46CF-B4E0-FAA04D56DC70

Q34379161-AA04970B-8A5F-4523-9D39-D8A4B89BBA0D

Q34379161-B13D8E6E-203C-463F-99F9-3A2724B4B26F

P2860

Q34379161-005C7E53-5DA3-4410-8187-89E15C20107D

Q34379161-0141133F-8E81-4B32-A1BE-37B326A7519F

Q34379161-01D82568-0F21-4AF1-8852-B154E16D8703

Q34379161-03AFE98A-912D-4334-827A-9A096E413B16

Q34379161-05AC74DC-25B8-4272-8615-A87215F831F2

Q34379161-09C146D7-82AF-4730-9CCD-7A9BA9F94002

Q34379161-0F81CC02-263C-4770-B17A-49DAEAE336ED

Q34379161-0F8E2ADA-4936-47A9-A367-9F21CD49556F

Q34379161-1A46ED2F-82C7-4719-93E0-7F197AA6C2BB

Q34379161-1EE6B861-96C7-48DB-9BA2-12CF2AAFDA4C

P304

Q34379161-CF9208B1-3867-41E8-9178-0AA2156B9A25

P31

Q34379161-68690E83-ABD3-438F-92BF-F0F115B1D144

P356

Q34379161-5721C671-14E5-4033-9DAA-3B9855772BD4

P433

Q34379161-C36B8AB3-3933-472A-9C48-2CEA4A950347

P478

Q34379161-2A310962-0595-4076-AB42-ABEA04487648

P577

Q34379161-A1E36400-08CC-42AE-9112-1B13128CB366

P5875

Q34379161-5554F79F-6569-4F52-9076-A9C1D576F6C2

P698

Q34379161-C2427C5D-83DC-4E67-8DFD-6F7FC618286F

P356

P1433

European Heart Journal

P1476

The severe cardiorenal syndrome: 'Guyton revisited'.

@en

P2093

Branko Braam

http://www.w3.org/2001/XMLSchema#string

Jaap A Joles

http://www.w3.org/2001/XMLSchema#string

Lennart G Bongartz

http://www.w3.org/2001/XMLSchema#string

Maarten Jan Cramer

http://www.w3.org/2001/XMLSchema#string

Pieter A Doevendans

http://www.w3.org/2001/XMLSchema#string

P2860

Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study

Acute myocardial infarction and renal dysfunction: a high-risk combination

Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress

beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling

p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells

Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure.

Production and actions of superoxide in the renal medulla.

Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor.

Reactive oxygen species mediate alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes.

Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase.

P304

11-17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHI020

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2004-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8114327

http://www.w3.org/2001/XMLSchema#string

P698

15615794

http://www.w3.org/2001/XMLSchema#string